Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in patients with pulmonary…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude Effects, High Altitude
- Trial name
- NCT07804576
- Testing
- Re-ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
Spironolactone for Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high.
- Trial name
- NCT01712620
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Arterial Hypertension (PAH), Premature Infants
PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension
The goal of this clinical trial is to evaluate the safety and potential efficacy of PNEUMOSTEM® for improving respiratory outcomes in very premature infants diagnosed with Early Pulmonary Arterial Hypertension.
- Trial name
- REVIVE-PH (NCT07368088)
- Testing
- PNEUMOSTEM®
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Samsung Medical Center
Pulmonary Hypertension, Right Heart Failure
RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation
Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown.
- Conditions
- Pulmonary Hypertension, Right Heart Failure, Heart Failure, Contractility
- Trial name
- Reserve (NCT04188756)
- Testing
- Exercise
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Giessen
Systemic Sclerosis, Pulmonary Hypertension
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
Trial Design Patients with borderline PAH indicated by borderline mPAP values will be included in this single centre study. This clinical investigation is performed as a Proof-of-Concept (PoC) investigator initiated trial (IIT)…
- Trial name
- EDITA (NCT02290613)
- Testing
- Ambrisentan
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
Pulmonary arterial hypertension is a chronic disease of the lung blood vessels resulting in constriction and high pressures. Treatment is given with a variety of drugs including the prostanoid class (e.g.
- Trial name
- NCT00705588
- Testing
- Tadalafil, Vardenafil
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Pulmonary Hypertension, Magnetic Resonance Imaging
4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension
Due to radiation exposure and low but real risk of morbidity and mortality associated with right heart catheterization, non-invasive procedures to estimate mPAP are desired for the diagnosis of PH or to monitor treatment…
- Conditions
- Pulmonary Hypertension, Magnetic Resonance Imaging, Pulmonary Arterial Pressure, Right Heart Catheterization
- Trial name
- HTPFLUW (NCT05103189)
- Testing
- 4D-flow sequence
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Pulmonary Arterial Hypertension
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH).
- Trial name
- NCT06907693
- Testing
- CT Pulmonary Angiography Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Prisma Health-Upstate
Pulmonary Arterial Hypertension
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
The purpose of this study is to assess the safety of ranolazine in people with pulmonary arterial hypertension (PAH) and who are receiving 1 or more background PAH therapies: ambrisentan, sildenafil,tadalafil, epoprostenol…
- Trial name
- NCT01757808
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Pulmonary Arterial Hypertension
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health…
- Trial name
- LIBERTY (NCT02664558)
- Testing
- ubenimex
- Where
- 31 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Eiger BioPharmaceuticals
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients.
- Trial name
- NCT01433328
- Testing
- Lidocaine
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Jewish General Hospital
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02246348
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Echosense Ltd.
Healthy, Healthy Adult
Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on sleeping parameters by polygraphy in healthy individuals, who live permanently >2600m.
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07801950
- Testing
- Descent from 2850m to sea level and re-ascent back to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension (PAH)
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
- Trial name
- ALEPH (NCT06987097)
- Testing
- Ambrisentan
- Volunteers
- 410 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.
- Trial name
- RAPID (NCT02847260)
- Testing
- Remodulin
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Systemic Sclerosis, Pulmonary Arterial Hypertension
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- DETECT (NCT00706082)
- Where
- 83 sites in United States, Austria and 18 more
- Volunteers
- 490 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Children
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years.
- Trial name
- NCT00159913
- Testing
- Sildenafil citrate
- Where
- 41 sites in United States, Brazil and 15 more
- Volunteers
- 235 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.